Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single, oral doses of ONC201 and the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects - Part A

Next Previous
X
Search
Trial Profile

A Phase 1, randomized study to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating single, oral doses of ONC201 and the effects of food on the bioavailability of ONC201 following oral administration in healthy adult subjects - Part A

Status: Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 04 Aug 2021

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Dordaviprone (Primary)
  • Indications Acute myeloid leukaemia; Adenocarcinoma; Breast cancer; Colorectal cancer; Endometrial cancer; Gallbladder cancer; Glioblastoma; Glioma; Liver cancer; Multiple myeloma; Myelodysplastic syndromes; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Sarcoma; Small cell lung cancer; Thyroid cancer
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Chimerix

    • Most Recent Events

    • 04 Aug 2021 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top